LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Paul W.H.I. Parren, Ph.D., executive vice president, head of research and development (R&D) at LAVA, will participate in three upcoming scientific conferences in November.

“Gamma delta T cells provide a highly promising effector cell modality,” said Paul W.H.I. Parren, Ph.D., executive vice president, head of R&D at LAVA. “I look forward to sharing data on several bispecific gamma delta T cell engagers derived from our Gammabody™ platform that pair potent and selective tumor cell killing with a low toxicity risk profile, thereby potentially translating into a wider therapeutic window. Our Gammabody™ platform provides a novel immuno-oncology approach to fight cancer.”

Details of Dr. Parren’s upcoming conference participation are as follows:

13^th Annual PEGS Europe Protein & Antibody Engineering Summit, Nov. 2-4, 2021, Barcelona & Virtual
Session Chair: Progress with Gamma Delta T Cell Therapies
Session Date/Time: Wed., Nov. 3, 2021 at 11:35 CET

European Antibody Congress Festival of Biologics, Nov. 9-11, 2021, Basel, Switzerland
Keynote Panel Discussion: Next generation antibody therapeutics: discovery, development and beyond
Panel Discussion Date/Time: Tues., Nov. 9, 2021 at 10:00 CET

Presentation: Bispecifics & Multispecifics Track – Bispecific gamma-delta T cell engagers
Presentation Date/Time: Tues., Nov. 9, 2021 at 14:00 CET

Session Chair: Bispecifics & Multispecifics Track
Session Date/Time: Tues., Nov. 9, 2021 at 15:40 CET

The Biotech Pharma Summit, Nov. 29-30, 2021, Porto, Portugal & Virtual
Virtual Presentation: Bispecific γδ T Cell Engagers for the Treatment of Cancer
Virtual Presentation Date/Time: Tues., Nov. 30, 2021 at 14:30 GMT

About LAVA Therapeutics

LAVA Therapeutics N.V. is a clinical-stage biotechnology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the treatment of solid tumors and hematological malignancies. The company’s innovative approach utilizes bispecific antibodies engineered to selectively kill cancer cells via the triggering of Vγ9Vδ2 T cell antitumor effector functions upon cross-linking to tumor associated antigens. A Phase 1/2a clinical study evaluating LAVA-051 in patients with certain hematological malignancies is enrolling patients (NCT04887259). The company currently anticipates data from the Phase 1 dose escalation phase of the study in the first half of 2022 with top line clinical data from the Phase 2a expansion cohorts expected in the second half of 2022. The company plans to initiate a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer in the fourth quarter of 2021. For more information, please visit www.lavatherapeutics.com and follow us on LinkedIn and Twitter.

LAVA’s Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including in respect of the company’s anticipated growth and clinical developments plans, including the timing of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody^TM platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. In addition, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACT
Catherine Day
+1-917-763-2709
This email address is being protected from spambots. You need JavaScript enabled to view it.